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Introduction: Since April 2007, health insurance funds in Germany are entitled to negotiate 
drug discount contracts (DDCs) with pharmaceutical manufacturers on particular drugs. 
DDCs commit pharmacists to dispense the drug made by this manufacturer. The aim of this 
study was to examine, how DDCs are implemented in pharmacies routines, and what 
implications DDCs have for everday drug supply. Methods: A standardized questionnaire on 
DDCs and their impact on drug supply was developed according to previous literature, piloted 
and distributed to pharmacies in Baden-Württemberg. Results: 804 pharmacists and 
pharmaceutical assistants participated in the study. The implementation of DDCs implies 
significant extra work for pharmacists, particulary additional need for counselling and 
education (99.1%), additional logistical requirements and more complex data processing 
needs. Patients are reported to get confused (97%), angry (96.9%) about intransparent drug 
substitutions, medication errors occur (60.1%). Conclusion: DDCs besides implications for 
prescibers and patients also have substantial impact on pharmacists and pharmacies. Adverse 
effects on drug supply and medication safety are possible or likely.  
 
 
 
Keywords: drug discount contracts, pharmacists, drug switching, substitution, drug safety 
 
List of abbreviations: DDC= drug discount contracts 
 
 
Background 
In Germany, a recently (April 2007) reformed federal Health Insurance Act (Sozialgesetzbuch 
5, SGB V) entitles health insurance funds to make contracts with pharmaceutical 
manufacturers  pertaining that members of the fund get the drug of the contract partner if 
prescribed an active ingredient regulated by the contract. If a patient holds a prescription of a 
brand name drug of a different manufacturer but the contract partner, pharmacists are liable 
not to hand out the prescribed but the contract-drug within certain substitution rules listed 
below.  
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Doctors may bypass the regulation for medical reasons by prescribing a brand name drug and 
ticking the ‘aut-idem-tickbox’ in the prescription form assuring that an individual patient gets 
hold of a particular brand name drug but discharging the Health Insurance Fund in part from 
their obligation to pay for the drug.  
The aim of the legal regulation is to reduce expenses by cheaper drug supply. 
 
Substitution rules include 
- identical active ingredient 
- identical  dosage 
- identical package size  
- same indication 
and the same or exchangeable galenics. The composition of additives (eg. alcohol, allergens, 
etc.) and also splitting properties of tablets to be substituted may vary (Pruszydlo et al. 2008). 
 
Despite detailed substitution rules patients have to face frequent changes in drug design and 
packaging. 
There is evidence that substitution of drugs may result in relevant patients’ confusion and 
medication errors (De Smet et al. 2007; Brekke et al. 2008; Sorensen et al. 2006) and that 
consultations with prescribing physicians are necessary (Hibbeler 2007). But it has been 
hardly explored what impact drug discount contracts have on the interaction of pharmacists 
and patients and what implication drug discount contracts have for patients’ information 
needs.  
 
As of August 2009, most of 186 health insurance funds and nearly 139 manufacturers 
participate in one or more of these discount contracts. To date, there are drug discount 
contracts concerning 29.206 drugs (Maag 2009) of roughly 56.660 (Pharma-Daten 2008) 
licensed in Germany. In 2009, the rate of rebated drugs amounts to 75% (Maag 2009). 
Logistics and management of substitution of such a huge amount of drugs is growing more 
complex and actually requires more than 18 million data sets to be controlled for in any 
prescription (Keller 2008). Also, logistics for procurement of drugs has become more 
complex and more prone to errors. In times when the first contracts started, there were often 
difficulties in the delivery by the pharmaceutical manufacturers. Storage capacity of 
pharmacies had to be extended (Hibbeler 2007).  
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Patients might be confused or feel frightened if they receive drugs with a modified package, 
similar drug names and tablets in a different shape, color or divisibility than the used one 
(Aronson 2004). Medication errors have been reported, the need for additional diagnostic and 
therapeutic procedures has been suspected and substantial individual health impact cannot be 
excluded. (Krämer et al. 2008, Meyer 2009, Otterbach 2008).  
 
Additional information needs and guidance provoke increasing service times in pharmacies 
with impact on patient/customer satisfaction. Also pharamcies’ customers get annoyed  about 
long waiting times at the pharmacies, because the customers need additional guidance or their 
drug isn`t available. Reliance between customer and pharmacist and drug adherence might 
suffer.  
 
So far, data on the impact of drug discount contracts to pharmacists, physician and patients 
are sparse. The aim of this study is to investigate how DDCs are implemented and what 
impact they have. To have an overview over their effects, affected groups, i.e. patients, 
doctors and pharmacists, were interviewed by self administered questionnaire about their 
experience with these contracts. Results of 2 studies have been submitted for publication. 
Here, data about the impact of drug discount contracts on pharmacies and on patients’ drug 
supply are reported. 
 
Methods  
For an overview of previous research on drug discount contracts a literature search in 
MEDLINE, EMBASE and COCHRANE was performed using keywords "drug discount 
contracts" or "compliance" or "tablet splitting," "drug switching" or "generic substitution" or 
"aut idem" or "adherence". In addition, a handsearch in german language journals such as 
"Zeitschrift für Allgemeinmedizin", "Deutsche Ärztezeitung" or the "Pharmazeutische 
Zeitung" was done.  
 
Based on this literature review and in collaboration with pharmacists, a questionnaire for 
pharmacies was developed and piloted in an iterative process. The survey instrument contains 
sociodemographic data like age, gender, profession and years of professional practice and 
data about the environment of the pharmacy. Participants were asked what impact drug 
discount contracts have on their daily work, about their difficulties with respect to staff and 
storage of the additional drugs, about information need, the behaviour of the patient`s 
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handling of the progress of substitution. Questions were answered by Likert-type answering 
scales ("true", "likely to be true," "tend not to be true" and "does not apply to") (Jamieson 
2004). 
 
The questionnaire was distributed as supplement in the member journal of 
“Landesapothekenkammer Baden-Württemberg”(Regional Chamber of Pharmacists) named 
“COSMAS” and was send out by the chamber to approx. 2750 pharmacies in B.-W. The 
questionnaire was returned anonymously to the authors.  
 
The study was approved by the Universities internal review board (No. 190/08). 
 
Data processing and Statistics 
Data were entered in a SAS database randomly controlled for correct input and evaluated by 
means of descriptive statistics. All variables were initially evaluated descriptively,analytical 
statistics was performed if applicable.  
 
Results 
The survey was conducted between September – December 2008. 804 questionnaires were 
returned from pharmacists (82.3%), PTA (pharmacist`s assistant) (13.7%) and PKA 
(pharmaceutical sales assistant) or other professions (4%) (PKA/other). 38% of respondents 
are male. 
 
In table 1 basic characteristics of the sample are presented.  
 
Furtheron, responses are reported without reference to professional level, unless otherwise 
noted. 
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Table 1 
 
Presentation of individual items  
A substantial majority of respondents (69%) report that they rarely get prescriptions that 
exclude substitution (“aut-idem-tickbox” ticked), and  30.9% report they get some such 
presciptions. 
 
According to pharmacists`questionnaire, they usually (82.5% on a Likert scale) receive 
prescriptions with the drug`s brand name on it. In contrast to other European countries, 
German pharmacists seldom receive prescriptions with the drug`s active ingredient noted 
(79.8% rejection on a Likert scale) (Figure 1). 
 
Figure 1 
 
A vast majority of respondents (98.3%) often have to switch drugs due to DDCs, and almost 
half of them (45.3%) admit that they occasionally do not have appropriate drugs for 
substitution in stock. 45.1 % report shortages of supply of appropriate drugs, and some 31% 
have encountered delivery problems of these drugs. Less than one fourth did not have 
substantial (21.6%) or did not have any (1.9%) supply problems with discount-drugs. 
 
One of the critiques against drug substitution is that splitting properties of tablets might differ 
substantially. 65.7 % (48.4 + 17.3) of pharmacists or their employees don`t know exactly 
about the splitting properties of individual drugs handed over to patients (Figure 2). 
 
Figure 2  
 
Almost all respondents (96.9%) report that customers react angry about getting an unknown 
drug. 97% of interviewees note that in their opinion the patients feel confused about handling 
of their drugs resulting from DDCs. Furthermore, 60.1% respondents specify that they know 
about medications errors of patients due to DDCs (Figure 3).  
 
Figure 3  
 
A vast majority (99.1%) report increased need for patients` counselling. 99.3% stated that the 
discount contracts have an important impact on the daily business. 93.8% indicate additional 
personnel expenses with respect to additional delivering servives of drugs to the patients.   In 
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Germany if a specific drug is not on stock in the pharmacy they order it and will deliver the 
medication to  patient’s home, usually on the same day (Figure 4). 
 
Figure 4  
 
In table 2, we present the results concerning extra payments, customers behaviour with 
respect to swapping drugs and additional patients` waiting time due to DDC.  
 
About 85% (24.5% and 59.9 % respectively) of respondents note that it happens more than 5 
times a week, that patients ask for not substituting their previously known drug, and 70 % 
(27.9 % and 42.2 % respectively) say that at least 5 times a week customers not only ask for, 
but insist on receiving their known drug. Likewise customers have to accept additional 
waiting time due to increased counselling and occasionally even higher surcharges. 
Furthermore over 70% report that they got threats of repayments (“Retaxierung”) by the 
health insurances up to 10 times per month (Table 2).  
 
Table 2  
 
Discussion 
By reforming the Health Insurance Act in 2007 and implementing drug discount contracts, 
new instruments have been effective in the regulation of drug supply installed with the aim to 
reduce cost for the Health Insurance Funds. 
Pharmacists now are overwhelmed by the sheer amount of 28.000 DCCs they have to control 
for each individual patient’s medication. 
 
The administration of drug discount contracts denotes a significant additional burden for 
pharmacies. This arises primarily due to the significant demand for explanation by the patient, 
manpower requirements, the challenging logistics and the technical processing of data. 
Additional personnel expenses by an additional service (delivery service) and a high increase 
of advice required by the customers have an important influence on the daily business. Also, 
half of the pharmacists do not know exactly if the substitution tablet is as well and exact 
divisible as the substituted one was. They must additionally look up in the Formulary. 
Pharmacists do have an increased need for patient-information and consultation due to the 
discount contracts.  
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But not only pharmacists bear an additional burden by the DDCs. Patients showed the same 
inconvenience. Medication errors do occur ( Rücker et al.; Mahler et al). It is evident that 
patients feel confused and angry because of the substitution (Rücker 2007; Wahl 2008). This 
also reflects in patients`  behavior towards pharmacists, because patients very often insist on 
or ask for their well-known medicine. Patients have more waiting time because of more 
additional advice or by delivery problems of the pharmaceutical companies (Haffke 2008).  
 
Physicians might specify not to change the priscribed drug on the prescription form to make 
sure that the patient continues to receive his usual medication. According to surveys by the 
„Kassenärztlichen Vereinigung Nordrhein” (Association of Statutory Health Insurance 
Physicians, Northrhine) majority of physicians never or only in individual cases are ticking 
the box “aut idem” (Neye 2008). This may be, because physicians are held liable for 
uneconomic prescription, on the part of the health insurance companies (Manthey 2008). 
Same applies for pharmacists. If they do not deliver the particular rebate drugs of the health 
insurance companies’ contractors, they might be held liable in a procedure called 
“Retaxierung” for additional costs of non-contractors’ drugs by the health insurance funds 
(Ehlers et al. 2001). 
 
Now, with DCCs in effect, health insurance funds directly interfere with historically evolved 
structures in the health care system. DCCs impose a fundamental reorganization of 
Germany’s drug supply by administrative means. Pharmacies’ and pharmacists’ self-concept 
and relationship to customers changes fundamentally. 
In the long run, pharmacies in Germany might have to give up their traditional role as an 
independent player and stakeholder in the health care system and turn more into a 
“dispensary-style” pharmacy to hand out a drug previously negotiated between health care 
funds and drug manufacturers. 
 
 
Limitations of the study 
Fundamental limitation of this study is the restriction to self reported appreciation of the 
impact of DDCs of pharmacists’ poise/attitude to medication supply and to self reported 
behaviour. No direct observations of pharmacists’ were made, reliability of pharmacists’ 
statements remains unknown. In this study, patients’ attitudes have only been reported by best 
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guess of pharamacists, no direct patient-generated data was part of this manuscript. Data of 
physicians’ and patients’ self reported attitudes are reported elsewhere. 
 
Due to a lack of basic data, this study could not be designed to evaluate effect size of DDCs’ 
impact on patients’ drug supply, medication adherence, potential adverse events and patients’ 
well being.  
 
Conclusion  
The DDCs denote a significant intervention in drug therapy. Pharmacists report on medication 
errors on the part of patients because of the discount contracts. Medication safety seems to be 
at risk. Further studies e.g. analysis of secondary data and for direct observations are 
necessary to evaluate the effect of these contracts agreements.The aim of the discount 
contracts should not focus on monetary aspects alone. One of the major ethical aims of 
modern medicine is respect for patients’ autonomy and it might be affected by DDCs.  
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Figure 1: Evaluation of the prescriptions. (Results of a four step Likert scale) 
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Figure 2 : Evaluation of the discount agreements with respect to storage, shortages of supply, the frequency of  
                 switching drugs and the knowledge of splitting of the tablets. (Results of a four step Likert scale –  
                  DDC= drug discount contracts) 
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Figure 3: Evaluation of the drug discount contracts with respect to customers behaviour, medications intake  
          an medications errors. . (Results of a four step Likert scale - DDC= drug discount contracts)  
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Figure 4: Evaluation of the discount agreements with respect to advice, addidional presonal and the influence on 
                 the day-to-day business. (Results of a four step Likert scale - DDC= drug discount contracts) 
 
  
 
Table 1: Age, years of profession by pharmacists, PTA, PKA/ other professions and pharmacy environment  
__________________________________________________________________________________________ 
  n minimum median maximum mean SD 
        
Age (years) Pharmacists    male 289 26 53 86 51.9 10.4 
 Pharmacists     female 337 25 47 83 47 10.5 
 PTA male - - - - - - 
 PTA  female 105 17 37 60 36.8 11.1 
 PKA/other      male - - - - - - 
 PKA/other      female 31 19 45 64 43.5 12.8 
 
years of profession < 2 years 2-5 years 5-20 years > 20 years 
     
 Pharmacists 1.1% 5.7% 34.9% 58.3% 
 PTA 9.4% 12.2% 45.8% 32.7% 
 PKA/other female 6.5% 6.5% 32.3% 54.8% 
 
Pharmacy environment rural suburb/provincial rather metropolitan 
    
 36.8% 48.9% 14.4% 
___________________________________________________________________________ 
Table
 1 
  
Table 2: Additional communication between pharmacies and customers. Financial performance and additional 
 waiting time for customers to switch medications based on the drug discount contracts 
__________________________________________________________________________________________ 
 
 never quite rare often 
Does it happens that customers have to pay more extra 
payment than before implementation of DDCs? 
 
 
10.4% 
 
80% 
 
9.6% 
_________________________________________________________________________________________________________________ 
 never <5 times 5-10 times > 10 times 
During the last week, how often have customers asked for 
their well-known drug? 
 
 
0.5% 
 
15.1% 
 
24.5% 
 
59.9% 
During the last week, how often did customers insist on their 
well-known drug? 
 
 
0.4% 
 
29.6% 
 
27.9% 
 
42.2% 
During the last week, how often did customers suffer delay 
of delivery, because th e discounted drug was out of stock? 
 
0.6% 
 
16.4% 
 
23.9% 
 
59.1% 
_________________________________________________________________________________________________________________ 
 yes no 
Did your pharmacy get a threat of “Retaxierung”, which 
means financal loss by health insurance companys 
 
70.1% 
 
29.9% 
_________________________________________________________________________________________________________________ 
 <5 times 5-10times > 10 times 
If yes. how many on average per month? 10.4% 80% 9.6% 
__________________________________________________________________________________________ 
 
 
List of changes 
 
1.  If a patient holds a prescription of a brand name drug of a different manufacturer but the 
contract partner, pharmacists…. 
 
2. Based on this literature review and in collaboration with pharmacists, a questionnaire for 
pharmacies was developed and piloted in an iterative process. 
 
3. 93.8% indicate additional personnel expenses with respect to additional delivering servives 
of drugs to the patients. 
 
4. In Germany if a specific drug is not on stock in the pharmacy they order it and will deliver 
the medication to  patient’s home, usually on the same day (Figure 4). 
Germany, traditionally, there is a service of lots of pharmacies. If a specific drug is not 
available, an employee will deliver medication to the patient’s home, usually  on the same day 
(Figure 4). 
 
5. Additional personnel expenses by an additional service (delivery service) and a high 
increase of advice required by the customers have an important influence on the daily 
business. 
 
6. This also reflects in patients`  behavior towards pharmacists, because patients very often 
insist on or ask for their well-known medicine. 
This also reflectespatient in behavior towards pharmacists , because patients very often insist 
or ak for their well-known medicine”. 
 
 
7. Patients (do) have more waiting time because of more additional advice or by delivery 
problems of the pharmaceutical companies (Haffke 2008). 
 
8. In the long run, pharmacies in Germany might have to give up their traditional role as an 
independent players and stakeholders in the health care system 
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